-
Idenix Pharmaceuticals LLC et al v. Gilead Sciences, Inc. DC CAFC
- 1:14-cv-00846
- D. Del.
- Judge: Leonard P. Stark
- Filed: 07/01/2014
- Closed: 03/14/2018
- Latest Docket Entry: 02/22/2022
- PACER
2
Plaintiffs
1
Defendant
1
Accused
Product
2
Patents-in-Suit
1,565
Days in
Litigation
-
Idenix Pharmaceuticals LLC et al v. Gilead Sciences, Inc. DC CAFC
- 1:14-cv-00846
- D. Del.
- Judge: Leonard P. Stark
- Filed: 07/01/2014
- Closed: 03/14/2018
- Latest Docket Entry: 02/22/2022
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method for the treatment of a hepatitis C virus infection, comprising administering an effective amount of a purine or pyrimidine β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
|
Invalid (112)
Entry 597 |
| 2 |
The method of claim 1, wherein the nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, is a pyrimidine nucleoside.
|
Invalid (112)
Entry 597 |
| 4 |
The method of claim 1, wherein the β-D-2′-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a phannaceutically acceptable salt or ester thereof is administered in combination or alternation with a second anti-hepatitis C agent.
|
Invalid (112)
Entry 597 |
| 5 |
The method of claim 4, wherein the second agent is selected from the group consisting of an interferon, ribavirin, a protease inhibitor, a thaizolidine derivative, a polymerase inhibitor, and a helicase inhibitor.
|
Invalid (112)
Entry 597 |
| 6 |
The method of claim 5, wherein the second agent is an interferon.
|
Invalid (112)
Entry 597 |
| 7 |
The method of claim 5, wherein the second agent is an ribavirin.
|
Invalid (112)
Entry 597 |
| 9 |
The method of claim 8, wherein the dosage unit contains 50 to 1000 mg.
|
Invalid (112)
Entry 597 |
| 10 |
The method of claim 8, wherein the dosage unit is a tablet or capsule.
|
Invalid (112)
Entry 597 |
| 16 |
The method of claim 1, wherein the βD-2′-methyl-ribofuranosyl nucleoside is administered in the form of a pharmaceutically acceptable ester.
|
Invalid (112)
Entry 597 |
| 19 |
The method of claim 16, wherein the nucleoside is a pyrimidine nucleoside.
|
Invalid (112)
Entry 597 |
| 23 |
The method of claim 1, wherein a phosphate, or a pharmaceutically acceptable salt thereof, of the β-D-2′-methyl-ribofuranosyl nucleoside is administered.
|
Invalid (112)
Entry 597 |
| 28 |
The method of claim 1, wherein the nucleoside or phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, is administered to a host.
|
Invalid (112)
Entry 597 |
| 29 |
The method of claim 28, wherein the host is a human.
|
Invalid (112)
Entry 597 |
| 30 |
A method for the treatment of a hepatitis C virus infection in a host, comprising contacting a hepatitis C virus in the host with a compound of claim 1 or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
|
Invalid (112)
Entry 597 |
| 31 |
A method for the treatment of a hepatitis C virus infection in a host, comprising contacting a cell in the host infected with a hepatitis C virus with a compound of claim 1 or a phosphate thereof, or a pharmaceutically acceptable salt or ester
view more
|
Invalid (112)
Entry 597 |
| All Claims |
NA
|
Valid (112)
Entry 518 |
-
Infringement
Gilead Sciences Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Pharmaceutical compositions containing sofosbuvirSofosbuvir | US 7,608,597 B2 |
1, 2, 4, 5, 7, 9, 10, 16, 19, 23, 28, 29, 30, 31
|
Willful infringement
Entry 533Entry 518 |
